logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10172815 B1

PDFFull Text
Date of Patent:
Jan. 08, 2019

Filed:

Nov. 07, 2014

Targeted treatment of anerobic cancer

Applicant:

University Hospitals Cleveland Medical Center, Cleveland, OH (US);

Inventors:

John R Haaga, Chagrin Falls, OH (US);

Rebecca Haaga, Chagrin Falls, OH (US);

Assignee:

UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER, Cleveland, OH (US);

Attorney:

Medlen & Carroll, LLP

Primary Examiner:

Karen A Canella

Int. Cl.
CPC ...
A61K 31/192 (2006.01); A61K 39/395 (2006.01); A61B 18/04 (2006.01); A61L 24/02 (2006.01); A61K 45/06 (2006.01); A61K 9/127 (2006.01); A61L 24/00 (2006.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/196 (2006.01); A61K 31/216 (2006.01); A61K 31/433 (2006.01); A61B 18/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/192 (2013.01); A61B 18/04 (2013.01); A61K 9/127 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/196 (2013.01); A61K 31/216 (2013.01); A61K 31/433 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61L 24/0015 (2013.01); A61L 24/02 (2013.01); A61B 2018/00577 (2013.01); A61K 2039/505 (2013.01); A61L 2300/436 (2013.01); A61L 2300/606 (2013.01); A61L 2430/36 (2013.01);
Abstract

The present invention relates to a pharmaceutical cocktail and methods of cancer treatment. In particular, one such cocktail comprises a combination of effective amounts of a lactate transporter inhibitor, a carbonic anhydrase inhibitor, a sodium potassium chloride cofactor (NKCC) transporter inhibitor, a member of the hydroxycinnamate class of drugs or a derivative thereof, and/or an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab in combination with blood vessel occlusion. As most cancers in an untreated state uses both aerobic and anaerobic/glycolytic pathways treatments contemplated herein can affect both metabolic pathways.

Find Patent Forward Citations

Loading…